Correction to: Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

  • Hiroshi Moro
  • Naoko Hattori
  • Yoshiaki Nakamura
  • Kana Kimura
  • Toshio Imai
  • Masahiro Maeda
  • Masakazu Yashiro
  • Toshikazu UshijimaEmail author

Correction to: Gastric Cancer

We recently published the priming effect of a DNA demethylating agent in chemotherapy of gastric cancer (original article). Unfortunately, there are errors in the units of some panels in Fig. 2. The units for SN38 (the most upper three panels) and PTX (the second bottom two panels) should be “nM”, instead of “µM”.

The errors were produced when the unit for 5-FU (the two bottom panels) was corrected from “nM” to “µM” during the production stage. Accidentally, the units for SN38 and PTX were also changed. A correct Fig. 2 is shown below.

The publisher sincerely apologize for the error.

Fig. 2

Effect of epigenetic priming by 5-aza-dC. Resistant cells were first treated with 5-aza-dC or mock first, and subsequently treated with a cytotoxic drug. The IC50 values were significantly lower for SN38 and CDDP, but not for PTX and 5-FU


Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Division of EpigenomicsNational Cancer Center Research InstituteTokyoJapan
  2. 2.Course of Advanced Clinical Research of CancerJuntendo University Graduate School of MedicineTokyoJapan
  3. 3.Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital EastChibaJapan
  4. 4.Central Animal DivisionNational Cancer Center Research InstituteTokyoJapan
  5. 5.Department of Surgical OncologyOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations